Omnicell (NASDAQ:OMCL) Trading Down 4.6% – Here’s Why

Shares of Omnicell, Inc. (NASDAQ:OMCL) were down 4.6% during mid-day trading on Tuesday . The stock traded as low as $42.52 and last traded at $43.1340. 608,322 shares were traded during mid-day trading, a decline of 4% from the average session volume of 634,329 shares. The stock had previously closed at $45.22.

Analyst Upgrades and Downgrades

OMCL has been the subject of several research reports. Wells Fargo & Company lifted their target price on Omnicell from $52.00 to $55.00 and gave the company an “overweight” rating in a research report on Thursday, April 23rd. Wall Street Zen raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 10th. KeyCorp lifted their price objective on shares of Omnicell from $60.00 to $70.00 and gave the company an “overweight” rating in a report on Tuesday, April 28th. Zacks Research lowered shares of Omnicell from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Finally, Craig Hallum reiterated a “buy” rating and set a $55.00 target price on shares of Omnicell in a report on Wednesday, April 29th. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $59.86.

Omnicell Stock Down 6.0%

The company has a quick ratio of 1.29, a current ratio of 1.50 and a debt-to-equity ratio of 0.13. The stock has a market cap of $1.93 billion, a PE ratio of 96.58, a price-to-earnings-growth ratio of 1.19 and a beta of 0.96. The firm has a fifty day moving average of $42.61 and a 200 day moving average of $41.50.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Tuesday, April 28th. The company reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.33 by $0.22. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.The business had revenue of $309.88 million during the quarter, compared to analysts’ expectations of $304.02 million. During the same period in the prior year, the firm posted $0.26 EPS. The business’s quarterly revenue was up 14.9% compared to the same quarter last year. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. On average, equities research analysts anticipate that Omnicell, Inc. will post 1.31 EPS for the current fiscal year.

Insider Buying and Selling

In other news, EVP Corey J. Manley sold 5,025 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $43.22, for a total transaction of $217,180.50. Following the completion of the sale, the executive vice president owned 112,783 shares in the company, valued at approximately $4,874,481.26. The trade was a 4.27% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Nnamdi Njoku sold 3,090 shares of the company’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $43.22, for a total transaction of $133,549.80. Following the completion of the transaction, the executive vice president owned 154,785 shares of the company’s stock, valued at approximately $6,689,807.70. The trade was a 1.96% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.92% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Omnicell

Several hedge funds have recently made changes to their positions in OMCL. Dimensional Fund Advisors LP lifted its holdings in shares of Omnicell by 6.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,450,385 shares of the company’s stock valued at $81,791,000 after purchasing an additional 137,834 shares during the last quarter. Wellington Management Group LLP lifted its stake in Omnicell by 156.4% in the fourth quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company’s stock valued at $94,014,000 after buying an additional 1,265,818 shares during the last quarter. Lazard Asset Management LLC boosted its holdings in shares of Omnicell by 3.8% in the second quarter. Lazard Asset Management LLC now owns 1,708,345 shares of the company’s stock valued at $50,225,000 after acquiring an additional 62,733 shares during the period. Sumitomo Mitsui Trust Group Inc. grew its position in shares of Omnicell by 2.0% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,410,865 shares of the company’s stock worth $47,095,000 after acquiring an additional 27,497 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Omnicell by 1.0% during the fourth quarter. Geode Capital Management LLC now owns 1,127,583 shares of the company’s stock worth $51,088,000 after acquiring an additional 11,424 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.